Clinical Trial 23059

A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Tamibarotene Plus Azacitidine Versus Placebo Plus Azacitidine in Newly Diagnosed Adult Patients Selected for RARA-positive Higher-risk Myelodysplastic Syndrome

Disease Site: Myeloid and Monocytic Leukemia

PI: Sallman, David

Clinical Trial 23063

An Open-label, Multicenter, Phase 2 Dose Optimization and Expansion Study to Evaluate the Safety and Efficacy of BB-1701, an anti-human epidermal growth factor receptor 2 (anti-HER2) antibody-drug conjugate (ADC), in Previously Treated Subjects with HER2-positive or HER2-low Unresectable or Metastatic Breast Cancer

Disease Site: Breast

PI: Han, Heather

Clinical Trial 21131

A Phase II Randomized Trial of Adjuvant Therapy with Pembrolizumab After Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma with High Risk Features

Disease Site: Larynx, Lip, Oral Cavity and Pharynx

PI: Kirtane, Kedar

Clinical Trial 21721

A Randomized Double-Blind Trial of Abatacept Extended Dosing Versus Abatacept Short-Term Dosing for Graft Versus Host Disease Prophylaxis: "ABA3"

Disease Site: Unknown Sites

PI: Pidala, Joseph

Clinical Trial 21450

A Phase 1/1b Dose Escalation and Expansion of CPX-351 in Combination with Gemtuzumab Ozogamicin in Newly Diagnosed Acute Myeloid Leukemia

Disease Site: Acute Leukemia (ALL, AML), Myeloid and Monocytic Leukemia

PI: Chan, Onyee

Clinical Trial 21035

A Pilot Study of Siltuximab in Large Granular Lymphocytic Leukemia (LGLL)

Disease Site: Lymphoid Leukemia

PI: Dong, Ning

Clinical Trial 21383

A Prospective, Randomized, Controlled, Open-label, Multicenter Trial to Evaluate Efficacy, Safety and Patient-reported Outcomes of Peptide Receptor Radionuclide Therapy (PRRT) with Lutetium (177Lu) Edotreotide compared to Best Standard of Care in Patients with Well-differentiated Aggressive Grade 2 and Grade 3, Somatostatin Receptor-positive (SSTR+), Neuroendocrine Tumors of GastroEnteric or Pancreatic Origin (COMPOSE)

Disease Site: Other Digestive Organ, Other Endocrine System

PI: Strosberg, Jonathan

Clinical Trial 20386

Targeting ODC as an Immunotherapeutic Target in STK11 (LKB1) Pathway-Deficient NSCLC

Disease Site: Lung

PI: Gray, Jhanelle

Clinical Trial 20339

Evolutionary Inspired Therapy for Newly Diagnosed, Metastatic, Fusion Positive Rhabdomyosarcoma

Disease Site: Bones and Joints, Rhabdomyosarcoma

PI: Metts, Jonathan

Clinical Trial 20110

GBM Agile: Global Adaptive Trial Master Protocol

Disease Site: Brain and Nervous System

PI: Grogan, Patrick

Clinical Trial 20415

A Phase III, Open-Label, Multicenter, Randomized Study Evaluating The Safety And Efficacy Of Polatuzumab Vedotin In Combination With RituximabI Plus Gemcitabine Plus Oxaliplatin (R-Gemox) Versus R-Gemox Alone In Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Disease Site: Myeloid and Monocytic Leukemia

PI: Sandoval-Sus, Jose

Clinical Trial 20641

A Randomized Pilot Trial of Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib and Binimetinib in Advanced Melanoma

Disease Site: Melanoma, skin

PI: Eroglu, Zeynep